Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

NICE

- PMLiVE

Vertex, NHS England and NICE finally reach agreement for Orkambi

Deal also includes Vertex’s other licensed cystic fibrosis medicines

- PMLiVE

NICE turns down Roche’s Tecentriq for triple-negative breast cancer

Will also not be included in the Cancer Drugs Fund

Webcast: Harnessing the power of social: How to generate fresh insights for your business using social media listening

Download our third Innovation in #MRX webcast, hosted in partnership with Convosphere, where we discuss how to use social media listening to answer key business questions.Watch here: https://bit.ly/2nM0xvj

Research Partnership

- PMLiVE

NICE delivers final ‘no’ for Novartis’ migraine treatment Aimovig

Blow to patients who have dubbed the treatment 'life-saving'

- PMLiVE

Takeda’s HAE drug Takhzyro backed by NICE

New treatment option for rare, hereditary disease

Biomarin

NICE approves BioMarin’s Brineura after initial setback

First treatment for rare disease

- PMLiVE

NICE backs NHS use of Novartis’ gene therapy Luxturna

First and only therapy for rare, inherited form of blindness

- PMLiVE

NICE’s long-serving chief exec Sir Andrew Dillon to step down

Pharma leader praises "laser focus" on thorny access questions

- PMLiVE

NICE’s fast-track catapults Skyrizi into market

Watchdog also gives direction on comparing rival treatments

- PMLiVE

Lynparza cleared as ovarian cancer maintenance therapy on Cancer Drugs Fund

Deal done with NHS England just weeks after EU approval

- PMLiVE

NICE unveils long-awaited review of methodologies

Use of quality of life measures to be reviewed

- PMLiVE

Pear Therapeutics submits latest digital therapeutic, insomnia and depression treatment

CBT-based treatment targets insomnia and depression

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links